Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab - Bristol-Myers Squibb

Drug Profile

Ipilimumab - Bristol-Myers Squibb

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; BioGene Pharmaceutical; Bristol-Myers Squibb; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Icahn School of Medicine at Mount Sinai; Intergroupe Francophone de Cancerologie Thoracique; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Medarex; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National University Hospital (Singapore); Northwestern University; Olivia Newton-John Cancer Research Institute; OncoTherapy Science; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University College London; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Registered Colorectal cancer
  • Preregistration Non-small cell lung cancer
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Oesophageal cancer; Prostate cancer; Small cell lung cancer; Urogenital cancer
  • Phase II Adrenocortical carcinoma; Breast cancer; CNS cancer; Gastrointestinal cancer; Genitourinary disorders; Gynaecological cancer; Liver metastases; Meningeal carcinomatosis; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Penile cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Phase I/II Diffuse large B cell lymphoma; Liver cancer; Lung cancer
  • Clinical Phase Unknown Glioma
  • No development reported HIV infections; Lymphoma

Most Recent Events

  • 24 Oct 2019 Bristol-Myers Squibb plans a phase I trial in breast cancer (Combination therapy, Late-stage disease, in adults and in elderly) in the US, in November 2019 (NCT04132817)
  • 28 Sep 2019 Updated efficacy and adverse events data from the phase III CheckMate-067 trial in Malignant melanoma released by Bristol-Myers Squibb
  • 26 Sep 2019 GERCOR and Bristol-Myers Squibb initiates a phase II for Oeso-gastric adenocarcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in France (IV) (NCT04006262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top